Blog Home


The National Center For Health Care Technology: Lessons Learned

January 22nd, 2009

A recent book, CRITICAL — What We Can Do About The Health-Care Crisis, authored by incoming “Health Czar” Tom Daschle, calls for the creation of a Federal Health Board (FHB). Among other proposed board functions, the FHB would “promote ‘high value’ medical care by recommending coverage of those drugs and procedures backed by solid evidence.”

This role sounds reminiscent of U.S. Department of Health and Human Services (DHHS) erstwhile National Center for Health Care Technology (NCHCT), whose charge was to assess the usefulness of established and new medical technologies. Although its tenure was short-lived (1979-82), one should learn from the NCHCT’s demise. I was there, and I offer the following reflections.

The NCHCT (having a $4 million budget and a staff of 20) was authorized in 1978 by Section 309 of the Public Health Service Act to conduct and sponsor assessments of health care technologies and to coordinate such efforts within the DHHS. The center was not regulatory and fulfilled two main functions:

1. Multifaceted assessments of technologies (e.g., safety, efficacy, effectiveness, and cost effectiveness, social, ethical and economic impacts), and

2. Scientific and medical evaluations for use in making Medicare coverage decisions (i.e., determining whether specific procedures are “reasonable and necessary” and thus appropriate for reimbursement by Medicare).

Reasons For The NCHCT’s Demise

Opponents of the NCHCT’s continuation — principally the Health Industry Manufacturers Association (now the Advanced Medical Technology Association) and the American Medical Association — argued that (1) physicians conduct their own technology assessments, so the NCHCT was redundant; (2) the NCHCT was a cost-control scheme in disguise; and (3) the NCHCT served as a health care industry regulator without codification of rules for decision making, a powerful charge in light of the anti-regulatory sentiments that swept into Washington in the early 1980s. When the Reagan administration eliminated the NCHCT by zeroing its budget for fiscal year 1982, its functions (to some extent) were transferred on to the National Center for Health Services Research (NCHSR), renamed the Agency for Health Care Policy and Research and later again renamed the Agency for Healthcare Research and Quality (AHRQ).

Challenges In Conducting Technology Assessment

Once a new medical technology is approved, there is tremendous pressure from investors to expand the market size (sales), both within the approved indication(s) and elsewhere (off-label applications). The NCHCT found itself under immense pressure to allow for a wide diffusion of new technologies. The following is a short list of the main challenges it faced in limiting technologies to those that were in fact both efficacious and cost-effective.

A dearth of data and studies. The NCHCT’s medical technology evaluation functions (principally focused on medical devices) were based on Food and Drug Administration (FDA) approval, published literature of early limited application, and professional opinion. In many cases, FDA approval hinged on whether use of the product could achieve a surrogate endpoint target (i.e., a lab value or other intermediate measure); the presumption was that the surrogate endpoint target was related to improvement in a clinical endpoint (improved survival, etc.). Other than these requisite FDA clinical trials, there was a dearth of studies to demonstrate real-world clinical effectiveness, a deficiency that lessened the ability of professional groups to comment on the product’s usefulness.

Expanded and off-label indications. Technologies that were covered by Medicare for a limited use quickly propagated to the treatment of patients having complications/comorbidities who were excluded from the requisite FDA clinical trials; for these patients, the benefits of the new technologies were unknown. Application of these technologies also propagated to other indications (off-label use) without the support of valid scientific evidence. As the Congressional Budget Office said recently, citing the findings of a RAND study, “Overuse occurs when a service is provided even though its risk of harm exceeds its likely benefit — that is, when it is not warranted on medical grounds. A more expansive definition would include cases in which the added costs of a more expensive service did not exceed the added benefits it was expected to provide.”

A Case Study Of Today’s Challenge

We use epoetin (EPOGEN) treatment of chronic anemia, a common complication of chronic kidney disease and end-stage renal disease (ESRD), as a case study to exemplify (1) attempts to expand the market, (2) studies necessary to assess these attempts, and (3) the translation of scientific evidence into policy formation. Documentation of epoetin therapy is unique because Medicare requires providers to submit monthly epoetin dosages and hematocrits for payment of this service. Medicare’s epoetin reimbursement policy also created a perverse financial incentive to overuse this drug.

Epoetin was introduced in 1989 to reduce the need for infusion of blood units for treatment of anemia among ESRD patients. Prior to availability of epoetin, blood units were frequently administered to approximately 10% of the ESRD patients (another 20% received an occasional blood unit for mild anemia). The remaining 70% of patients did not receive blood unit infusion for treatment of anemia. By 2005, however, 99% of in-center hemodialysis patients received epoetin treatment. How did this therapy diffuse to near-universal use among the dialysis population? Was this diffusion backed up by solid scientific evidence? How can it be that a comprehensive technology assessment has not been conducted more than two decades after epoetin has been on the market?

Epoetin dosing levels have changed dramatically since the substance’s  introduction into the U.S. market. The mean dose of epoetin has increased about fourfold in dialysis patients, and Medicare expenditures for epoetin rose to ~$2 billion in 2004, constituting 11% of all Medicare ESRD costs. Unfortunately, other than studies documenting usefulness for a small group of patients who would otherwise be dependent on infusion of blood units, there are no other clinical trials to guide policymakers on how to cover and/or reimburse for this costly treatment. Despite this deficit of valid scientific evidence, Medicare has consistently covered/reimbursed for the expanded use, costing the Medicare program over $20 billion to date.

In an attempt to increase sales of approved indications and expand to other indications, proponents commissioned both clinical trials and highly flawed observational studies that ended with conflicting results. Justification for this prodigious expenditure continues to rest with the presumption that a positive change in the surrogate endpoint (in this case, hematocrit) is related to an improvement in a clinical endpoint (improved survival, quality of life, etc.), despite the fact that this has been disproved by clinical trials and disallowed by the FDA.

Our epoetin research addresses the translation of epoetin research into practice (today, over 99% of dialysis patients receive this drug continuously) and the role of government in requiring and applying scientific evidence to policy formation. The two existing clinical trials (Besarab, 1998, and Singh, 2006) were terminated due to higher mortality rates in the higher target hematocrit treatment arms. Unfortunately, there are no other clinical trials to guide policymakers on how to pay for this costly treatment. Our contention is that Medicare policymakers should base their decisions on future payment for this service and others on a reasonable demonstration of “real-world” clinical effectiveness.


Rapid diffusion of costly health care technologies with undocumented benefits is endemic to the soaring costs of the U.S. health care system. Our case study is unique because epoetin dose and physiological response (hematocrit) data are readily available to assess the benefits of chronic anemia epoetin treatment on a continuous basis. This case study (and cautionary tale) is offered to the proposed Federal Health Board as an example of the advantage of enhancing Medicare claims to obtain vital information to assess benefits, as well as the pitfalls — both fiscally and in terms of patient safety — of not conducting a comprehensive technology assessment.

Email This Post Email This Post Print This Post Print This Post

 to the #1 source of health policy research.

No Trackbacks for “The National Center For Health Care Technology: Lessons Learned”

5 Responses to “The National Center For Health Care Technology: Lessons Learned”

  1. Dennis Cotter Says:

    Rapid diffusion of costly health care technologies with undocumented benefits is endemic to the soaring costs of the U.S. health care system.Our case study is unique because epoetin dose and physiological response(hematocrit) data are readily available to assess the benefits of chronic anemia epoetin treatment on a continuous basis. However,technology assessment in the US appears to be a daunting task, because as Richard Smith past editor of the British Medical Journal points out… “Only about 15% of medical interventions are supported by solid scientific evidence… This is partly because only 1% of the articles in medical journals are scientifically sound and partly because many treatments have never been assessed at all.” Therefore, maintaining the integrity of how CMS’ National Coverage Decision (NCD) assessments are conducted, and how, based on those assessments, coverage determinations are made, is paramount. As the readers of this blog are likely to know, CMS has issued a nondecision on moving forward with an NCD regarding ESA coverage and reimbursement.

    According to CMS, the only documented benefit found in their analysis of epoetin is “increasing hemoglobin.” This lab value is a surrogate endpoint that has not been correlated with hard clinical endpoints such as improved survival or improved quality of life. CMS claims that they put “less emphasis on” findings based on surrogate endpoints but their non-decision decision to continue coverage status quo contradicts such claims because a surrogate endpoint of elevated hemoglobin is the only documented benefit of costly epoetin treatments they decided to continue unabated. In fact, CMS put the least emphasis on studies reporting hard endpoints e.g., mortality and adverse events, because they deem these studies to be “low” quality. Traditionally, documented death and other adverse events are deemed by all regulators and policy makers to have the greatest weight in developing health care policy. For example, in the case of epoetin, the same studies that CMS discounted prompted FDA to take numerous urgent actions to restrict epoetin use. By reversing their traditional approach to weighing evidence, CMS runs the risk of being viewed as arbitrary and capricious in their attempts to maintain the epoetin status quo. Furthermore, patients not subjected to ESRD PPS include the millions of anemic CKD pre-dialysis patients , who could be subjected once again to gaming of the reimbursement system and who are at risk for both increased mortality and cardiovascular risks as a result of high ESA doses. By not issuing an affirmative decision regarding risk, a great disservice is done to these vulnerable populations.

    MTPPI will convene its
    TAC in June
    to plan the next steps in assessing the consequences of CMS’ proposed non-decision on ESAs for CKD pre-dialysis and dialysis patients.

  2. Dennis Cotter Says:

    Dr. Amerling and Mr. Peckham raise interesting political and clinical practice observations regarding the function of a Federal Health Board (FHB). Using our decade of epoetin research findings, I’ll restrict my response on the proposed FHB functions to two of their comments: 1.) “practice guidelines that threaten the practice of individualized medicine today; and how to 2.) “decide what is appropriate medical care for everyone.” It’s my understanding that the Board would have three principal functions: a) expanding the Federal Employee Health Benefit Program to non-Federal persons; b) aligning high-quality of care incentives with diffusion of technology; and c) promoting high value medical care. The first two secular tasks are formidable and necessary, but I’ll restrict my comments to the third clinical task — using epoetin as an example of a conundrum created when evidentiary standards are relaxed. Over the past twenty years, there has been a vigorous debate regarding the “benefit” of leveling the hematoctit among anemic dialysis patient populations. Randomized clinical trials (RCTs) have consistently shown that patients assigned to higher hematocrit target levels (and receiving higher epoetin doses) do not show improvements in survival, hospitalization, or cardiac outcomes and in fact, patients at higher hematocrit targets might be at increased risk for adverse events that include death, myocardial infarction, vascular access thrombosis, increased use of antihypertensive medications, and cerebrovascular events. To date, analysis of RCTs have not been disaggregated by response to epoetin, patient demographics or co-morbidities when evaluating patient outcomes. Disregarding risks related to higher epoetin dose levels, the continuing use of a single hematocrit target range (promoted by clinical practice guidelines, reimbursement policy, and performance standards) ignores individual patient needs expressed by Dr. Amerling.

    This concern has invigorated a new debate whether individualized patient strategies are needed for epoetin anemia management therapy (i.e. How does responsiveness to epoetin therapy affect patient outcome? How does the presence of co-morbidities affect outcomes? How do patient demographics affect outcome?). In this circumstance, the FHB could recognize this unmet quality-of-care need, catalyze research, and provide new insights to facilitate the patient-physician consultation. Using existing Medicare claims data, such an analysis could provide, at the patient-level, a basis for improved outcomes using ‘individualized’ guidelines based on common patient characteristics and, at the national level, lead to more cost-effective third-party payer policies.

  3. acavale Says:

    I agree with ramerling that this idea of a centralised board decding the appropriatness of medical care is outrageous. It will only take one of those that propose this idea to be on the receiving side to realise that it is the end of the physician-patient relationship. It might also mean the end to medical practice, since only algorithms can manage all care based on clearinghouse rules. In our haste to rectify what is not working properly, we should not break down all that is working well or the fundamentals of providing and receiving medical care.

  4. Bill Peckham Says:

    Good post, it raises some questions. If this Federal Health Board had been in place in 1989 what would have happened that didn’t? Who sets the goal we’re trying to achieve? Sure survival is nice but I’d call it the ante not an end point. Shouldn’t we be aiming higher? To employment for those of the right age and then extending that level of care to those past retirement – this was the suggestion in New Views, I think we need a 60,000ft view to guide any new gatekeepers as we all pursue of optimal dialysis, this Federal Health Board sounds to be much closer to the weeds.

  5. ramerling Says:

    Interesting history lesson, Dennis. The Agency for Healthcare Research and Quality now hosts the National Guideline Clearing House, home to thousands of practice guidelines that threaten the practice of individualized medicine today.
    A federal “health board” would be a devastating blow to the medical profession, and to millions of patients. It is the ultimate central planning fantasy/nightmare: A handful of political appointees get to decide what is “appropriate” medical care for everyone. It is not just about cost control, it is about control, pure and simple. When citizens have to petition bureaucrats for this new medication or that new procedure, we will no longer be a free society. Decisions on what medications and procedures are appropriate for individual patients should be made exclusively by the patient in consultation with their physician. Perhaps the payer thinks they are entitled to a say, and certainly no payer should be obliged to cover anything and everything. A return to the system of self-pay for most routine expenses should restore a sense of balance about how far to go. But there is no way that a central committee of so-called experts should be involved. This is truly Soviet style medicine.
    Please see my recent letter in the Wall Street Journal, commenting on this issue:

Leave a Reply

Comment moderation is in use. Please do not submit your comment twice -- it will appear shortly.

Authors: Click here to submit a post.